透析依赖合并射血分数降低心衰患者的RAS抑制治疗:系统评价与荟萃分析
本研究通过系统评价与荟萃分析评估ARNI与ACEI/ARB在透析依赖合并HFrEF患者中的疗效与安全性。结果显示ARNI与非ARNI方案相比全因死亡率显著降低(HR 0.78,95%CI 0.71-0.87),ACEI/ARB与对照相比全因死亡率(HR 0.76,95%CI 0.68-0.84)和心血管死亡率(HR 0.62,95%CI 0.54-0.71)均降低,但证据主要来自观察性研究。
要点
- ARNI与非ARNI方案相比,透析依赖HFrEF患者全因死亡率显著降低(HR 0.78,95%CI 0.71-0.87)。
- ACEI/ARB与对照相比全因死亡率(HR 0.76,95%CI 0.68-0.84)和心血管死亡率(HR 0.62,95%CI 0.54-0.71)均降低。
- ARNI与心血管死亡率无显著关联(HR 0.91,95%CI 0.79-1.04),安全性数据仅来自ARNI研究。
核心结论
- 在透析依赖合并HFrEF患者中,ARNI与非ARNI方案相比及ACEI/ARB与对照相比均与较低全因死亡率相关,但心血管死亡率降低仅见于ACEI/ARB治疗。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、EMBASE、Google Scholar和Web of Science至2025年12月,纳入成人维持性血透或腹透的慢性HFrEF患者研究。
- 共纳入6项ARNI研究(治疗组3818例,对照组4344例)和3项ACEI/ARB研究(治疗组3293例,对照组1982例),合并HR及95%CI。
主要发现
- ARNI与非ARNI方案相比,全因死亡率合并HR 0.78(95%CI 0.71-0.87)。
- ACEI/ARB与安慰剂或无RAS阻断相比,全因死亡率合并HR 0.76(95%CI 0.68-0.84),心血管死亡率合并HR 0.62(95%CI 0.54-0.71)。
- ARNI与心血管死亡率无显著关联(合并HR 0.91,95%CI 0.79-1.04)。
- 安全性数据仅来自ARNI研究,提示与ACEI/ARB相比未增加低血压且高钾血症风险更低。
临床怎么用
- 对于透析依赖合并HFrEF患者,可考虑使用ARNI或ACEI/ARB以降低全因死亡率,但需注意证据主要来自观察性研究。
- ACEI/ARB可能额外降低心血管死亡率,临床决策时应结合患者个体情况并监测安全性。
局限性
- 证据主要来自观察性研究,易受残余混杂影响,不能解释为因果治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Evidence supporting renin-angiotensin system (RAS) inhibition in dialysis-dependent patients with heart failure with reduced ejection fraction (HFrEF) remains limited. We performed a systematic review and meta-analysis to assess the efficacy and safety of angiotensin receptor-neprilysin inhibitors (ARNIs) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) in this population (PROSPERO ID: CRD420251274393). METHODS: Outcomes of interest included all-cause mortality and cardiovascular mortality. Eligible studies included adult patients with chronic HFrEF on maintenance hemodialysis or peritoneal dialysis, comparing ARNI versus non-ARNI regimens and ACEi/ARB versus control regimens. Literature searches were conducted through December 2025 in PubMed, EMBASE, Google Scholar, and Web of Science. Hazard ratios (HRs) and their respective 95% confidence intervals (CIs) were pooled and meta-analyzed across studies. RESULTS: Overall, six studies evaluated ARNIs (3,818 treated; 4,344 controls), and three studies evaluated ACEi/ARBs (3,293 treated; 1,982 controls). ARNI use versus non-ARNI regimens was associated with significantly lower all-cause mortality (pooled HR 0.78, 95% CI 0.71-0.87), as was ACEi/ARB initiation versus placebo or no RAS blockade (pooled HR 0.76, 95% CI 0.68-0.84). ACEi/ARB therapy was also associated with lower cardiovascular mortality (pooled HR 0.62, 95% CI 0.54-0.71), whereas no significant association was observed with ARNIs (pooled HR 0.91, 95% CI 0.79-1.04). Safety data were available only for ARNI studies, suggesting no excess hypotension and a lower risk of hyperkalemia compared with ACEi/ARBs. CONCLUSIONS: In dialysis-dependent patients with HFrEF, ARNI use versus non-ARNI regimens, and ACEi/ARB use versus placebo or no RAS blockade, were each associated with lower all-cause mortality, while lower cardiovascular mortality was observed only with ACEi/ARB therapy. These findings suggest a potential overall benefit of RAS blockade in this population; however, they are derived predominantly from observational studies, remain susceptible to residual confounding and should not be interpreted as demonstrating causal treatment effects.
引用
- Sritharan A, Marchetti M, Antiochos P, et al. Renin-Angiotensin System Inhibition in Dialysis-Dependent Patients with Chronic Heart Failure due to Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. Nephrol Dial Transplant. 2026. PMID: 42584660. doi:10.1093/ndt/gfag184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。